Kevin Krause, will be speaking at the CAN-AMR Net Antibiotic Drug Discovery Training: From Al-Enabled Discovery to Successful Commercialization on April 1.

ArrePath will be at the 44th Annual J. P. Morgan Healthcare Conference during January 12-15. Contact us to set up a meeting!

ArrePath’s President & CEO, Kevin Krause, is a featured session speaker on Al Drug Discovery & Therapeutics Pitch Session at the Med x Tech Summit Asia

ArrePath’s President & CEO, Kevin Krause, is a featured panelist on Antimicrobial Resistance: The Urgent Global Response at the World Medical Innovation Forum happening September 15-17, 2025 at the Encore Boston Harbor.

ArrePath announced several business updates. First, the company has raised the next round of financing to advance its pipeline and continue to expand the scope and capabilities of its discovery platform. The Boehringer Ingelheim Venture Fund led the financing, which also included existing investors Insight Partners, Innospark, and Nor’easter Ventures, and new investor AB Magnitude. 

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) will award biotechnology company ArrePath US$3.7 million to execute a Lead Optimization workplan for its first-in-class antibiotic targeting a clinically novel target for the treatment of complicated urinary tract infections caused by multidrug-resistant (MDR) Enterobacterales.

Join us at ESCMID 2025 from April 11-15 in Vienna, Austria. Our CEO Kevin Krause, our CSO Alita Miller, and our Head of Chemistry Deidre Johns will be in attendance hearing about the latest breakthroughs in Infectious Diseases R&D

Join ArrePath’s Chief Technology Officer, Kurt Thorn, for a live webinar titled “Charting New Frontiers in Artificial Intelligence for Antibiotic Design” on April 3, 2025.

ArrePath today announced the appointment of Kevin Krause as President and Chief Executive.

ArrePath today announced that it has been awarded a £1 million non-dilutive grant from PACE (Pathways to Antimicrobial Clinical Efficacy) in support of its efforts to develop a new class of antibiotics designed to address multidrug-resistant (MDR) infections, a growing global health threat.